CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion

Junhee Park; Xianglan Zhang; Sun Kyoung Lee; Na Young Song; Seung Hwa Son; Ki Rim Kim; Jae Hoon Shim; Kwang Kyun Park; Won Yoon Chung

doi:10.1172/JCI125336

CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion

Junhee Park, Xianglan Zhang, Sun Kyoung Lee, Na Young Song, Seung Hwa Son, Ki Rim Kim, Jae Hoon Shim, Kwang Kyun Park, Won Yoon Chung

Department of Oral Biology

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Oral squamous cell carcinoma (OSCC) frequently invades the maxillary or mandibular bone, and this bone invasion is closely associated with poor prognosis and survival. Here, we show that CCL28 functions as a negative regulator of OSCC bone invasion. CCL28 inhibited invasion and epithelial-mesenchymal transition (EMT), and its inhibition of EMT was characterized by induced E-cadherin expression and reduced nuclear localization of β-catenin in OSCC cells with detectable RUNX3 expression levels. CCL28 signaling via CCR10 increased retinoic acid receptor-β (RARβ) expression by reducing the interaction between RARα and HDAC1. In addition, CCL28 reduced RANKL production in OSCC and osteoblastic cells and blocked RANKL-induced osteoclastogenesis in osteoclast precursors. Intraperitoneally administered CCL28 inhibited tumor growth and osteolysis in mouse calvaria and tibia inoculated with OSCC cells. RARβ expression was also increased in tumor tissues. In patients with OSCC, low CCL28, CCR10, and RARβ expression levels were highly correlated with bone invasion. Patients with OSCC who had higher expression of CCL28, CCR10, or RARβ had significantly better overall survival. These findings suggest that CCL28, CCR10, and RARβ are useful markers for the prediction and treatment of OSCC bone invasion. Furthermore, CCL28 upregulation in OSCC cells or CCL28 treatment can be a therapeutic strategy for OSCC bone invasion.

Original language	English
Pages (from-to)	5381-5399
Number of pages	19
Journal	Journal of Clinical Investigation
Volume	129
Issue number	12
DOIs	https://doi.org/10.1172/JCI125336
Publication status	Published - 2019 Dec 2

Bibliographical note

Funding Information:
bone invasion. Intraperitoneally administered CCL28 prevented osteolysis in athymic nude mice inoculated with OSCC cells. The anti-osteoclastogenic activity of CCL28 was supported by the reduced number of TRAP-positive osteoclasts detected at the interface between tumor and bone tissues. Tumor growth was also inhibited by CCL28 treatment, and the in vivo inhibitory activity of CCL28 on tumor growth may be due to a decrease in the release of bone matrix–derived growth factors by osteoclast-mediated bone resorption rather than the direct inhibition of OSCC cell viability. Increased RARβ expression was detected in the tumor tissues of CCL28-treated mice. Furthermore, we confirmed that CCL28 overexpression in OSCC cells can also reduce tumor growth and osteolysis. These findings support the in vitro results demonstrating that CCL28 inhibits OSCC bone invasion by upregulating RARβ.

Funding Information:
We thank Chae-Eun Lee from the Oral Science Research Institute for providing technical assistance with μCT. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1901).

All Science Journal Classification (ASJC) codes

Medicine(all)

Access to Document

10.1172/JCI125336

Fingerprint Dive into the research topics of 'CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion'. Together they form a unique fingerprint.

Cite this

@article{fb1a53d552a94ba5a57f0d6a98b00fc6,

title = "CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion",

abstract = "Oral squamous cell carcinoma (OSCC) frequently invades the maxillary or mandibular bone, and this bone invasion is closely associated with poor prognosis and survival. Here, we show that CCL28 functions as a negative regulator of OSCC bone invasion. CCL28 inhibited invasion and epithelial-mesenchymal transition (EMT), and its inhibition of EMT was characterized by induced E-cadherin expression and reduced nuclear localization of β-catenin in OSCC cells with detectable RUNX3 expression levels. CCL28 signaling via CCR10 increased retinoic acid receptor-β (RARβ) expression by reducing the interaction between RARα and HDAC1. In addition, CCL28 reduced RANKL production in OSCC and osteoblastic cells and blocked RANKL-induced osteoclastogenesis in osteoclast precursors. Intraperitoneally administered CCL28 inhibited tumor growth and osteolysis in mouse calvaria and tibia inoculated with OSCC cells. RARβ expression was also increased in tumor tissues. In patients with OSCC, low CCL28, CCR10, and RARβ expression levels were highly correlated with bone invasion. Patients with OSCC who had higher expression of CCL28, CCR10, or RARβ had significantly better overall survival. These findings suggest that CCL28, CCR10, and RARβ are useful markers for the prediction and treatment of OSCC bone invasion. Furthermore, CCL28 upregulation in OSCC cells or CCL28 treatment can be a therapeutic strategy for OSCC bone invasion.",

author = "Junhee Park and Xianglan Zhang and Lee, {Sun Kyoung} and Song, {Na Young} and Son, {Seung Hwa} and Kim, {Ki Rim} and Shim, {Jae Hoon} and Park, {Kwang Kyun} and Chung, {Won Yoon}",

note = "Funding Information: bone invasion. Intraperitoneally administered CCL28 prevented osteolysis in athymic nude mice inoculated with OSCC cells. The anti-osteoclastogenic activity of CCL28 was supported by the reduced number of TRAP-positive osteoclasts detected at the interface between tumor and bone tissues. Tumor growth was also inhibited by CCL28 treatment, and the in vivo inhibitory activity of CCL28 on tumor growth may be due to a decrease in the release of bone matrix–derived growth factors by osteoclast-mediated bone resorption rather than the direct inhibition of OSCC cell viability. Increased RARβ expression was detected in the tumor tissues of CCL28-treated mice. Furthermore, we confirmed that CCL28 overexpression in OSCC cells can also reduce tumor growth and osteolysis. These findings support the in vitro results demonstrating that CCL28 inhibits OSCC bone invasion by upregulating RARβ. Funding Information: We thank Chae-Eun Lee from the Oral Science Research Institute for providing technical assistance with μCT. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1901).",

year = "2019",

month = dec,

day = "2",

doi = "10.1172/JCI125336",

language = "English",

volume = "129",

pages = "5381--5399",

journal = "Journal of Clinical Investigation",

issn = "0021-9738",

publisher = "The American Society for Clinical Investigation",

number = "12",

}

CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion. / Park, Junhee; Zhang, Xianglan; Lee, Sun Kyoung; Song, Na Young; Son, Seung Hwa; Kim, Ki Rim; Shim, Jae Hoon; Park, Kwang Kyun; Chung, Won Yoon.

In: Journal of Clinical Investigation, Vol. 129, No. 12, 02.12.2019, p. 5381-5399.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - CCL28-induced RARβ expression inhibits oral squamous cell carcinoma bone invasion

AU - Park, Junhee

AU - Zhang, Xianglan

AU - Lee, Sun Kyoung

AU - Song, Na Young

AU - Son, Seung Hwa

AU - Kim, Ki Rim

AU - Shim, Jae Hoon

AU - Park, Kwang Kyun

AU - Chung, Won Yoon

N1 - Funding Information: bone invasion. Intraperitoneally administered CCL28 prevented osteolysis in athymic nude mice inoculated with OSCC cells. The anti-osteoclastogenic activity of CCL28 was supported by the reduced number of TRAP-positive osteoclasts detected at the interface between tumor and bone tissues. Tumor growth was also inhibited by CCL28 treatment, and the in vivo inhibitory activity of CCL28 on tumor growth may be due to a decrease in the release of bone matrix–derived growth factors by osteoclast-mediated bone resorption rather than the direct inhibition of OSCC cell viability. Increased RARβ expression was detected in the tumor tissues of CCL28-treated mice. Furthermore, we confirmed that CCL28 overexpression in OSCC cells can also reduce tumor growth and osteolysis. These findings support the in vitro results demonstrating that CCL28 inhibits OSCC bone invasion by upregulating RARβ. Funding Information: We thank Chae-Eun Lee from the Oral Science Research Institute for providing technical assistance with μCT. This research was supported by a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI15C1901).

PY - 2019/12/2

Y1 - 2019/12/2

N2 - Oral squamous cell carcinoma (OSCC) frequently invades the maxillary or mandibular bone, and this bone invasion is closely associated with poor prognosis and survival. Here, we show that CCL28 functions as a negative regulator of OSCC bone invasion. CCL28 inhibited invasion and epithelial-mesenchymal transition (EMT), and its inhibition of EMT was characterized by induced E-cadherin expression and reduced nuclear localization of β-catenin in OSCC cells with detectable RUNX3 expression levels. CCL28 signaling via CCR10 increased retinoic acid receptor-β (RARβ) expression by reducing the interaction between RARα and HDAC1. In addition, CCL28 reduced RANKL production in OSCC and osteoblastic cells and blocked RANKL-induced osteoclastogenesis in osteoclast precursors. Intraperitoneally administered CCL28 inhibited tumor growth and osteolysis in mouse calvaria and tibia inoculated with OSCC cells. RARβ expression was also increased in tumor tissues. In patients with OSCC, low CCL28, CCR10, and RARβ expression levels were highly correlated with bone invasion. Patients with OSCC who had higher expression of CCL28, CCR10, or RARβ had significantly better overall survival. These findings suggest that CCL28, CCR10, and RARβ are useful markers for the prediction and treatment of OSCC bone invasion. Furthermore, CCL28 upregulation in OSCC cells or CCL28 treatment can be a therapeutic strategy for OSCC bone invasion.

AB - Oral squamous cell carcinoma (OSCC) frequently invades the maxillary or mandibular bone, and this bone invasion is closely associated with poor prognosis and survival. Here, we show that CCL28 functions as a negative regulator of OSCC bone invasion. CCL28 inhibited invasion and epithelial-mesenchymal transition (EMT), and its inhibition of EMT was characterized by induced E-cadherin expression and reduced nuclear localization of β-catenin in OSCC cells with detectable RUNX3 expression levels. CCL28 signaling via CCR10 increased retinoic acid receptor-β (RARβ) expression by reducing the interaction between RARα and HDAC1. In addition, CCL28 reduced RANKL production in OSCC and osteoblastic cells and blocked RANKL-induced osteoclastogenesis in osteoclast precursors. Intraperitoneally administered CCL28 inhibited tumor growth and osteolysis in mouse calvaria and tibia inoculated with OSCC cells. RARβ expression was also increased in tumor tissues. In patients with OSCC, low CCL28, CCR10, and RARβ expression levels were highly correlated with bone invasion. Patients with OSCC who had higher expression of CCL28, CCR10, or RARβ had significantly better overall survival. These findings suggest that CCL28, CCR10, and RARβ are useful markers for the prediction and treatment of OSCC bone invasion. Furthermore, CCL28 upregulation in OSCC cells or CCL28 treatment can be a therapeutic strategy for OSCC bone invasion.

UR - http://www.scopus.com/inward/record.url?scp=85075960649&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85075960649&partnerID=8YFLogxK

U2 - 10.1172/JCI125336

DO - 10.1172/JCI125336

M3 - Article

C2 - 31487270

AN - SCOPUS:85075960649

VL - 129

SP - 5381

EP - 5399

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 12

ER -